{
  "id": "NCLEX_NGN_TREND_500721771",
  "itemType": "trend",
  "caseId": "STROKE_TPA_SAFETY_500",
  "seedId": "MISSION-500-72-1771347494184",
  "topic": "Pharmacological & Parenteral Therapies",
  "subtopic": "Thrombolytics",
  "nclexClientNeed": "Physiological Integrity",
  "nclexSubClientNeed": "Pharmacological and Parenteral Therapies",
  "cognitiveSkill": "Analyzing Cues; Generating Solutions; Taking Action",
  "bloom": "Analyzing",
  "difficulty": 4,
  "status": "active",
  "itemStem": "The nurse in the emergency department is caring for a 68-year-old client diagnosed with an acute ischemic stroke. The stroke team has evaluated the client and an order for alteplase has been entered. Review the client's record. \n\n**Select the 4 findings that require immediate follow-up.**\n\n**Which potential complication is the client at highest risk for developing?**\n\n**For each nursing action, specify if it is Indicated or Contraindicated to perform at this time.**",
  "tabs": [
    {
      "id": "tab1",
      "label": "Nurses' Notes",
      "content": "**1300:** Client, a 68-year-old Spanish-speaking male, arrives via EMS from a local farm where he works. Onset of symptoms (right-sided facial droop, right arm plegia, expressive aphasia) was 0230 ago per a coworker. Client has a history of hypertension with poor medication adherence. A hospital-approved translation device is being used for communication, which is limited due to aphasia. NIH Stroke Scale (NIHSS) score is 15. Non-contrast head CT and labs sent. Stroke team activated. \n\n**1415:** Non-contrast head CT results reviewed, showing no hemorrhage. Labetalol 10 mg IV administered for blood pressure management. Client's BP is now within the parameters for alteplase administration. Stroke team has placed the order for alteplase. Awaiting pharmacy delivery."
    },
    {
      "id": "tab2",
      "label": "Vital Signs",
      "content": [
        {
          "Time": "1300 (Admission)",
          "BP": "194/112",
          "HR": "92",
          "RR": "18",
          "SpO2": "97% on RA",
          "Temp": "37.1°C (98.8°F)"
        },
        {
          "Time": "1345 (Post-Labetalol)",
          "BP": "178/104",
          "HR": "86",
          "RR": "16",
          "SpO2": "98% on RA",
          "Temp": "N/A"
        },
        {
          "Time": "1420 (Current)",
          "BP": "172/98",
          "HR": "84",
          "RR": "16",
          "SpO2": "98% on RA",
          "Temp": "N/A"
        }
      ]
    },
    {
      "id": "tab3",
      "label": "Laboratory Results",
      "content": [
        {
          "Test": "WBC",
          "Result": "8.9 x 10³/µL",
          "Reference Range": "4.5-11.0"
        },
        {
          "Test": "Hemoglobin",
          "Result": "14.5 g/dL",
          "Reference Range": "13.5-17.5"
        },
        {
          "Test": "Hematocrit",
          "Result": "43%",
          "Reference Range": "41-53%"
        },
        {
          "Test": "Platelets",
          "Result": "82,000/mm³",
          "Reference Range": "150,000-450,000"
        },
        {
          "Test": "INR",
          "Result": "1.0",
          "Reference Range": "0.8-1.2"
        },
        {
          "Test": "aPTT",
          "Result": "31 seconds",
          "Reference Range": "25-35"
        },
        {
          "Test": "Glucose, Random",
          "Result": "155 mg/dL",
          "Reference Range": "<200"
        },
        {
          "Test": "Creatinine",
          "Result": "1.1 mg/dL",
          "Reference Range": "0.6-1.2"
        },
        {
          "Test": "Troponin T",
          "Result": "<0.01 ng/mL",
          "Reference Range": "<0.04"
        }
      ]
    },
    {
      "id": "tab4",
      "label": "Diagnostic Findings",
      "content": "**Non-Contrast Head CT Report:**\n\n**Impression:** No evidence of acute intracranial hemorrhage, mass, or hydrocephalus. Subtle loss of grey-white differentiation in the left middle cerebral artery (MCA) territory suggestive of early ischemic changes. No contraindications to thrombolytic therapy from a radiographic standpoint."
    },
    {
      "id": "tab5",
      "label": "MAR",
      "content": [
        {
          "Medication": "Normal Saline 0.9%",
          "Dose": "75 mL/hr",
          "Route": "IV",
          "Status": "Infusing"
        },
        {
          "Medication": "Labetalol",
          "Dose": "10 mg",
          "Route": "IV PUSH",
          "Status": "Administered at 1340"
        },
        {
          "Medication": "Alteplase (tPA)",
          "Dose": "Per stroke protocol",
          "Route": "IV Infusion",
          "Status": "Pending Administration"
        }
      ]
    }
  ],
  "scoringModel": [
    {
      "partId": "part1",
      "type": "multiPoint",
      "scoring": {
        "type": "plusMinus",
        "points": 1
      },
      "layout": {
        "stem": "Select the 4 findings that require immediate follow-up.",
        "options": [
          {
            "id": "p1_opt_1",
            "label": "Platelet count of 82,000/mm³"
          },
          {
            "id": "p1_opt_2",
            "label": "Expressive aphasia"
          },
          {
            "id": "p1_opt_3",
            "label": "Blood pressure of 172/98 mmHg"
          },
          {
            "id": "p1_opt_4",
            "label": "Onset of symptoms 0230 ago"
          },
          {
            "id": "p1_opt_5",
            "label": "Non-contrast head CT result"
          },
          {
            "id": "p1_opt_6",
            "label": "Alteplase order pending"
          },
          {
            "id": "p1_opt_7",
            "label": "Client is Spanish-speaking"
          }
        ]
      },
      "correctAnswer": {
        "value": [
          "p1_opt_1",
          "p1_opt_3",
          "p1_opt_5",
          "p1_opt_6"
        ]
      }
    },
    {
      "partId": "part2",
      "type": "cloze",
      "scoring": {
        "type": "dichotomous",
        "points": 1,
        "match": {
          "exact": true
        }
      },
      "layout": {
        "stem": "Which potential complication is the client at highest risk for developing?",
        "cloze": [
          {
            "type": "text",
            "value": "Which potential complication is the client at highest risk for developing? "
          },
          {
            "type": "dropdown",
            "id": "p2_cloze_1",
            "options": [
              "Hemorrhagic transformation of stroke",
              "Aspiration pneumonia",
              "Hypertensive crisis",
              "Anaphylactic reaction to alteplase"
            ]
          }
        ]
      },
      "correctAnswer": {
        "value": {
          "p2_cloze_1": "Hemorrhagic transformation of stroke"
        }
      }
    },
    {
      "partId": "part3",
      "type": "matrix",
      "scoring": {
        "type": "dichotomous",
        "points": 1,
        "match": {
          "exact": true
        }
      },
      "layout": {
        "stem": "For each nursing action, specify if it is Indicated or Contraindicated to perform at this time.",
        "rows": [
          {
            "id": "p3_row_1",
            "label": "Administer the alteplase infusion as ordered."
          },
          {
            "id": "p3_row_2",
            "label": "Notify the healthcare provider of the platelet count."
          },
          {
            "id": "p3_row_3",
            "label": "Prepare the client for a thrombectomy procedure."
          },
          {
            "id": "p3_row_4",
            "label": "Place the client on strict NPO status."
          }
        ],
        "columns": [
          {
            "id": "p3_col_1",
            "label": "Indicated"
          },
          {
            "id": "p3_col_2",
            "label": "Contraindicated"
          }
        ]
      },
      "correctAnswer": {
        "value": [
          {
            "rowId": "p3_row_1",
            "columnId": "p3_col_2"
          },
          {
            "rowId": "p3_row_2",
            "columnId": "p3_col_1"
          },
          {
            "rowId": "p3_row_3",
            "columnId": "p3_col_2"
          },
          {
            "rowId": "p3_row_4",
            "columnId": "p3_col_1"
          }
        ]
      }
    }
  ],
  "answerBreakdown": {
    "part1": [
      {
        "optionId": "p1_opt_1",
        "rationale": "**Correct.** A platelet count of 82,000/mm³ is significantly below the normal range (150,000-450,000/mm³). This indicates thrombocytopenia, which is a critical contraindication for alteplase administration. Alteplase is a thrombolytic agent that works by breaking down blood clots. In a client with thrombocytopenia, the risk of bleeding, particularly intracranial hemorrhage, is significantly increased. Immediate follow-up is essential to prevent potentially fatal complications. *Clinical Pearl: Remember the mnemonic 'STOP' for tPA contraindications: Signs of hemorrhage, Thrombocytopenia, Other bleeding risks, Prior stroke/surgery.*",
        "correct": true
      },
      {
        "optionId": "p1_opt_2",
        "rationale": "**Incorrect.** Expressive aphasia, characterized by difficulty producing speech, is a common neurological deficit following a stroke, particularly affecting the dominant hemisphere (usually the left). While it requires supportive care and communication strategies, it is an expected symptom of the stroke itself and not a finding that directly contraindicates alteplase administration or requires immediate intervention in the context of alteplase safety.",
        "correct": false
      },
      {
        "optionId": "p1_opt_3",
        "rationale": "**Correct.** A blood pressure of 172/98 mmHg, while elevated, is now within the acceptable range for alteplase administration, which generally requires blood pressure to be below 185/110 mmHg. The initial elevated BP was addressed with labetalol. However, continuous monitoring is crucial. Uncontrolled hypertension significantly increases the risk of hemorrhagic transformation after alteplase administration. *Clinical Pearl: Maintain BP <180/105 mmHg post-tPA for 24 hours.*",
        "correct": true
      },
      {
        "optionId": "p1_opt_4",
        "rationale": "**Incorrect.** The onset of stroke symptoms 0230 ago is a critical piece of information for determining alteplase eligibility. Alteplase is most effective when administered within 3-4.5 hours of symptom onset. This information confirms the client is within the treatment window, making it an inclusion criterion rather than a finding requiring immediate follow-up in the context of a contraindication.",
        "correct": false
      },
      {
        "optionId": "p1_opt_5",
        "rationale": "**Correct.** The non-contrast head CT result is a crucial finding because it rules out intracranial hemorrhage. Hemorrhage is an absolute contraindication to alteplase therapy. The CT scan confirms that the client's symptoms are likely due to an ischemic stroke and that thrombolytic therapy can be considered (with other contraindications ruled out). *Pathophysiology: Alteplase activates plasminogen to form plasmin, which degrades fibrin, the main component of blood clots. If a hemorrhage is present, alteplase would worsen the bleeding.*",
        "correct": true
      },
      {
        "optionId": "p1_opt_6",
        "rationale": "**Correct.** The pending order for alteplase is a significant cue. The nurse must verify the appropriateness of the order based on the client's current condition and lab results. This includes confirming the absence of contraindications, such as the client's low platelet count. This is a critical point for error prevention.",
        "correct": true
      },
      {
        "optionId": "p1_opt_7",
        "rationale": "**Incorrect.** The client being Spanish-speaking is a health equity consideration that affects communication and requires the use of appropriate translation services. However, it is not a clinical finding that directly impacts the decision to administer alteplase or requires immediate follow-up in the context of alteplase safety.",
        "correct": false
      }
    ],
    "part2": [
      {
        "option": "Hemorrhagic transformation of stroke",
        "rationale": "**Correct.** Hemorrhagic transformation is the most serious potential complication in this scenario due to the client's thrombocytopenia (platelet count of 82,000/mm³). Alteplase increases the risk of bleeding, and a low platelet count further impairs the body's ability to form clots and stop bleeding. This can lead to a hemorrhagic stroke, which is often fatal or results in severe disability. *Pathophysiology: Alteplase's mechanism of action involves breaking down clots. In the presence of thrombocytopenia, the body lacks sufficient platelets to repair any vascular damage caused by the thrombolysis, leading to hemorrhage.*",
        "correct": true
      },
      {
        "option": "Aspiration pneumonia",
        "rationale": "**Incorrect.** While aspiration pneumonia is a risk for stroke clients due to potential dysphagia, it is not the most immediate and life-threatening complication in this specific situation. The client's low platelet count poses a more immediate and critical risk of hemorrhage if alteplase is administered.",
        "correct": false
      },
      {
        "option": "Hypertensive crisis",
        "rationale": "**Incorrect.** Although hypertension is a risk factor for stroke and needs to be managed, the client's blood pressure is currently within the acceptable range for alteplase administration after treatment with labetalol. Therefore, hypertensive crisis is not the most immediate risk.",
        "correct": false
      },
      {
        "option": "Anaphylactic reaction to alteplase",
        "rationale": "**Incorrect.** Anaphylaxis is a possible adverse reaction to any medication, including alteplase. However, it is a relatively rare occurrence. The client's thrombocytopenia presents a much higher and more immediate risk of hemorrhagic complications.",
        "correct": false
      }
    ],
    "part3": [
      {
        "rowId": "p3_row_1",
        "rationale": "**Contraindicated.** The client's platelet count of 82,000/mm³ is an absolute contraindication to alteplase administration. Administering alteplase in this situation would significantly increase the risk of intracranial hemorrhage and other serious bleeding complications. This is a critical safety concern. *Clinical Pearl: Always double-check lab values, especially platelet count and coagulation studies, before administering thrombolytics.*",
        "correctColumnId": "p3_col_2"
      },
      {
        "rowId": "p3_row_2",
        "rationale": "**Indicated.** The nurse has a duty to advocate for the client's safety. Notifying the healthcare provider of the low platelet count is essential to ensure that the alteplase order is reviewed and potentially canceled. This allows the provider to consider alternative treatment options or address the thrombocytopenia before proceeding with thrombolysis.",
        "correctColumnId": "p3_col_1"
      },
      {
        "rowId": "p3_row_3",
        "rationale": "**Contraindicated.** While thrombectomy is a potential treatment option for some ischemic strokes, it is not the immediate priority in this situation. The client's low platelet count first needs to be addressed. Furthermore, the decision to proceed with thrombectomy depends on specific criteria, such as the location and size of the clot, which are not detailed in the provided information.",
        "correctColumnId": "p3_col_2"
      },
      {
        "rowId": "p3_row_4",
        "rationale": "**Indicated.** Placing the client on strict NPO (nothing by mouth) status is a standard precaution for all acute stroke clients. This is because stroke can impair swallowing function, increasing the risk of aspiration. Maintaining NPO status until a swallow evaluation is performed helps prevent aspiration pneumonia.",
        "correctColumnId": "p3_col_1"
      }
    ]
  },
  "sentinelStatus": "healed_v2026_v8"
}